Xenetic Biosciences Analyst Price Targets - Benzinga

Xenetic Biosciences Inc

XBIONASDAQ

Trade with Public

Trade with Public

$2.05

-0.07-3.3%

Ult. Agg.: Oct 30, 8:45 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Confronta Rapporto azionario

Xenetic Biosciences Analyst Price Targets - Benzinga

Xenetic Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xenetic Biosciences (XBIO).

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 9, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Mar 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Dec 5, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Nov 22, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Aug 20, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) with a Neutral.

Benzinga Newsdesk

Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences

Vandana Singh